Sargramostim (GM-CSF) + PD-1
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT04703426 |
|
Recruitment Status :
Withdrawn
(Study terminated by sponsor)
First Posted : January 11, 2021
Last Update Posted : May 22, 2023
|
Sponsor:
Dana-Farber Cancer Institute
Collaborator:
Partner Therapeutics (PTx)
Information provided by (Responsible Party):
Elizabeth Buchbinder, MD, Dana-Farber Cancer Institute
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
Study was withdrawn before participants were enrolled.
| Recruitment Status : | Withdrawn |
|---|---|
| Estimated Primary Completion Date : | June 10, 2024 |
| Estimated Study Completion Date : | June 9, 2025 |